Australia has one of the highest rates of melanoma in the world and as a result, it is often referred to as ‘Australia’s national cancer’. Skin GPs and Dermatologists play an important role in identifying suspected melanoma and referring patients for assessment and treatment. In the new era of adjuvant immunotherapies for completely resected Stage III/IV melanoma, sentinel lymph node biopsy (SLNB) plays an important role in determining whether patients are eligible for therapy.
This 1-hour RACGP accredited activity aims to equip Skin GPs and Dermatologists with the information they need to assist oncologists in ensuring that eligible patients with completely resected Stage III/IV melanoma have access to adjuvant immunotherapy and are supported throughout their treatment.
It features two cases studies and expert video interviews from the multidisciplinary faculty.
This program is supported by an independent educational grant provided from Bristol Myers Squibb.